BCMA

Product List

Creative Biolabs is committed to advancing the field of MM treatment through the development of state-of-the-art anti-BCMA CAR T-cell therapies. Our comprehensive suite of anti-BCMA CAR related products and sophisticated in vitro and in vivo assays underscore our dedication to providing effective and lasting therapeutic solutions.

Background

B cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a member of the tumor necrosis factor receptor superfamily. It plays a crucial role in B-cell maturation and differentiation into plasma cells. Structurally, BCMA comprises three major domains: an extracellular domain, a transmembrane domain, and a cytoplasmic domain. Notably, BCMA is almost exclusively found on plasma cells and is overexpressed during malignant transformations, making it a specific and compelling target for multiple myeloma (MM) treatments.

Associated Disease

• Multiple Myeloma

Anti-BCMA CAR-T Services

Anti-BCMA CAR-T In Vitro Assays

• Anti-BCMA CAR Construct Design

Creative Biolabs offers a range of BCMA-targeting CAR constructs to assist customers' projects.

Fig.1 Schematic of different Anti-BCMA constructs.¹

• Anti-BCMA CAR-T Expression Test

CAR expression test is an essential test for CART development, which can verify specific CAR expression levels to facilitate subsequent development processes. Creative Biolabs provides robust CAR expression tests by various methods, such as WB, FACS, and qPCR.

Fig.2 The anti-BCMA CAR expression was detected by flow cytometry.¹

• Phenotype Analysis of Anti-BCMA CART

In vitro characterization of CAR-T cells is critical to evaluate their potential efficacy before clinical application. Creative Biolabs has launched several phenotype tests to assess the performance of CART cells, such as T cells subpopulation analysis, exhaustion marker test, activation marker test, etc.

Fig.3 Phenotypic analysis of different anti-BCMA CAR T cells after activation. (Panel A: CD8+ and CD4+ T cell subtypes, panel B: T cell subpopulations for T cell differentiation status).¹

• Anti-BCMA CAR-T Cytokine Release Test

Creative Biolabs specializes in comprehensive cytokine production assays to measure the release of various cytokines, such as IFN-γ, IL-2, and TNF-α, following CAR-T cell activation. Enhanced cytokine production is indicative of robust CAR-T cell activation and anti-tumor efficacy.

Fig.4 IFN-γ secretion detection of different anti-BCMA CART cells against target cells.¹

• Anti-BCMA CAR-T In Vitro Cytotoxicity Assay

Cytotoxicity assays are performed using MM cell lines expressing BCMA as target cells. These assays assess the ability of CAR-T cells to recognize and lyse BCMA-expressing tumor cells, providing pivotal data on the therapeutic potential of CAR-T constructs.

Fig.5 Cytotoxic assay of different anti-BCMA CART cells against target cells.¹

Anti-BCMA CAR-T In Vivo Assays

• Efficacy Test of Anti-BCMA CAR-T

The efficacy of anti-BCMA CAR-T cells is evaluated in vivo using mouse models engrafted with human MM cell lines. These studies are pivotal in demonstrating tumor reduction and assessing the long-term persistence of CAR-T cells post-administration. Creative Biolabs provides several in vivo models that are designed to mimic clinical scenarios, providing relevant insights into the potential clinical performance of CAR-T therapies.

• Safety and Toxicity Evaluation

Safety and toxicity are paramount considerations in CAR-T cell therapy development. Creative Biolabs conducts comprehensive toxicity assessments to monitor potential adverse effects, such as off-target activity and cytokine release syndrome (CRS). These evaluations ensure that anti-BCMA CAR-T cells are not only effective but also safe for clinical application, adhering to regulatory standards.

Fig.6 In vivo antitumor activity of anti-BCMA CAR T cells in U266 xenograft model.¹

Reference

1. Stock, Sophia, et al. "Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma." Cancer Immunology, Immunotherapy 73.6 (2024): 100.